Deutsche Bank AG Buys Shares of 120,333 Elanco Animal Health Incorporated $ELAN

Deutsche Bank AG purchased a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 120,333 shares of the company’s stock, valued at approximately $2,961,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. UBS Group AG increased its holdings in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the period. Sei Investments Co. lifted its holdings in Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after buying an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after buying an additional 3,717,404 shares during the period. Invesco Ltd. boosted its position in Elanco Animal Health by 336.0% during the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after acquiring an additional 3,690,735 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Elanco Animal Health during the 2nd quarter valued at $83,958,000. 97.48% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on ELAN shares. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. KeyCorp raised their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, TD Cowen increased their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Stock Performance

Shares of ELAN stock opened at $25.09 on Thursday. Elanco Animal Health Incorporated has a 12-month low of $17.11 and a 12-month high of $27.98. The business’s fifty day simple moving average is $24.61 and its 200-day simple moving average is $24.01. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The company has a market cap of $12.54 billion, a PE ratio of -61.20, a PEG ratio of 1.50 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter last year, the firm earned $0.26 EPS. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, Director Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $23.68 per share, with a total value of $236,800.00. Following the transaction, the director directly owned 111,687 shares of the company’s stock, valued at $2,644,748.16. This trade represents a 9.83% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This represents a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 63,198 shares of company stock worth $1,473,109 over the last ninety days. 1.14% of the stock is currently owned by insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.